Journal: The Journal of Infectious Diseases

Article Title: Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

doi: 10.1093/infdis/jiaf395

Figure Lengend Snippet: Study design. * The index date for the 1-dose and 2-dose cohorts was the date of receipt of the first and second RZV dose, respectively. The index date for unvaccinated patients corresponded to that of the vaccinated patients. Note: Propensity score matching was done at the index date. For each AID condition and sensitivity analyses, separate propensity scores and different sets of potential confounders were included. For stratified analysis with matched variables, individuals were matched on AID condition, age group, and medication category; then 1:3 matched on propensity scores with the list of covariates. Abbreviations: AID, autoimmune disease; CDM, Optum Clinformatics® Data Mart Database; HZ, herpes zoster; IR, incidence rate; non-RZV cohort, unvaccinated patients; RZV, adjuvanted recombinant zoster vaccine; RZV cohort, RZV-vaccinated patients; US, United States; VE, vaccine effectiveness; ZVL, live-attenuated varicella-zoster virus vaccine.

Article Snippet: We conducted a retrospective matched cohort study using Optum's deidentified Clinformatics® Data Mart Database datasets from January 2018 to December 2021.

Techniques: Recombinant, Virus